Drug Profile

Research programme: immunomodulator therapeutics - ESSA Pharma

Alternative Names: PR 031; PR023; RLM 023

Latest Information Update: 09 Oct 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Puricore
Developer Realm Therapeutics
Class Anti-inflammatories; Antiacnes; Small molecules
Mechanism of Action Immunomodulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued Acne vulgaris; Inflammation

Most Recent Events

09 Oct 2025 ESSA Pharma has been acquired by XenoTherapeutics
31 Jul 2019 Realm Therapeutics has been acquired and merged into ESSA Pharma
17 Sep 2018 Discontinued - Preclinical for Acne vulgaris in USA (Topical)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com